Myopathy in Patients Taking Atorvastatin: A Pilot Study.

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Statin therapy is widely used for cardiovascular disease prevention.
• Statin-induced myopathy is a known adverse effect, but its prevalence and dose-dependency require further investigation.
• Atorvastatin is a commonly prescribed statin.

Purpose of the Study:

• To determine the prevalence of statin-induced myopathy in patients taking atorvastatin.
• To identify risk factors associated with atorvastatin-induced myopathy.
• To evaluate the relationship between atorvastatin dosage and the occurrence of myopathy.

Main Methods:

• A cohort of 200 patients aged 40 years or older, receiving atorvastatin (≥10 mg/day) for at least two weeks, was studied.
• Patient history, anthropometry, and biochemical markers including thyroid stimulating hormone (TSH) and Vitamin D levels were assessed.
• Myopathy features were explained, and its frequency was analyzed in relation to atorvastatin dose and patient demographics.

Main Results:

• The overall frequency of myopathy was 7.5%, significantly increasing with higher atorvastatin doses (1.4% at 10 mg, 10% at 20 mg, 12.8% at 40 mg; P < 0.05).
• Myopathy occurred more frequently in females (8.65%) than males (6.25%).
• No significant differences in TSH or Vitamin D levels were observed between patients with and without myopathy.

Conclusions:

• Atorvastatin use is associated with a significant incidence of myopathy in real-world clinical settings.
• The risk of developing myopathy escalates with increasing doses of atorvastatin.
• Dose optimization and patient monitoring are essential to mitigate statin-induced myopathy.